2022 / 06

Next Paper
DOI: 10.24075/brsmu.2022.065

ORIGINAL RESEARCH

The rs17713054 and rs1800629 polymorphisms of genes LZTFL1 and TNF are associated with COVID-19 severity

Traspov AA1, Minashkin MM1, Poyarkov SV1, Komarov AG2, Shtinova IA2, Speshilov GI2, Karbyshev IA2, Pozdniakova NV1, Godkov MA3
About authors

1 Sistema BioTech LLC, 109235 Moscow, Russia

2 State Budget Institution Of Health Of The City Of Moscow "Diagnostic Center (Center For Laboratory Research) Of The Department Of Health Of The City Of Moscow" Russian Federation, , Moscow

3 Sklifosovskiy Research Institute for Emergency Medical Aid, Moscow, Russia

Correspondence should be addressed: Natalia V. Pozdnyakova
1 Kurjanovskaja, 34, korp. 11, Moscow, Russia; ur.hcetoibametsis@avokayndzop.n

About paper

Funding: the study was supported by the major Sistema BioTech LLC shareholder, the Sistema Public Joint Stock Financial Corporation. The study was funded by the Moscow Department of Health as part of the double blind clinical trial.

Acknowledgements: the authors express their gratitude to Antipova YuO, Deputy Head of the Moscow Department of Health, for organizing the blind clinical trial of COVID-19 severity and the patients of the Diagnostic Center (Center of Laboratory Testing) of the Moscow Department of Health for the provided biomaterial samples.

Author contribution: Pozdnyakova NV, Poyarkov SV — study concept and design; Minashkin MM — molecular genetic research, laboratory tests; Poyarkov SV, Traspov AA — literature review, manuscript writing; Traspov AA — statistical processing of the results, manuscript editing; Komarov AG — project management, planning the experiment, data analysis; Shtinova IA, Speshilov GI, Karbyshev IA — providing clinical data and metadata; Godkov MA — control over clinical sample collection at the Sklifosovsky Research Institute for Emergency Medicine, providing anonymized data.

Compliance with ethical standards: the study did not need to be approved by the Ethics Committee because of dealing with anonymized patient data and the double blind study format.

Received: 2022-11-18 Accepted: 2022-12-14 Published online: 2022-12-28
|
  1. Hu B, et al., Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19 (3): 141‒54.
  2. Gupta K, et al., Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022; 844: 146790.
  3. Severe Covid GG, et al., Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; 383 (16): 1522‒34.
  4. Colona VL, Vasiliou V, Watt J, Novelli G, Reichardt JKV. Update on human genetic susceptibility to COVID-19: susceptibility to virus and response. Hum Genomics. 2021; 15 (1): 57.
  5. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021; 131 (23): e152386.
  6. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet. 2021; 22 (3): 137‒53.
  7. El-Hefnawy SM, et al, COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities. Gene Rep. 2022; 27: 101612.
  8. Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. 2022; 185 (17): 3086‒103.
  9. Mohlendick B, et al. The GNB3 c.825C>T (rs5443) polymorphism and protection against fatal outcome of corona virus disease 2019 (COVID-19). Front Genet. 2022; 13: 960731.
  10. Chen T, et al. A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19. mBio. 2021; 12 (5): e0137221.
  11. Minashkin MM, et al. The Role of Genetic Factors in the Development of Acute Respiratory Viral Infection COVID-19: Predicting Severe Course and Outcomes. Biomedicines. 2022; 10 (3).
  12. Fricke-Galindo I, Buendía-Roldán I, Ruiz A, Palacios Y, Pérez-Rubio G, de Jesus Hernández-Zenteno R, et al. TNFRSF1B and TNF Variants Are Associated With Differences in Levels of Soluble Tumor Necrosis Factor Receptors in Patients With Severe COVID-19. J Infect Dis. 2022; 226 (5): 778‒87.
  13. Downes DJ, et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. 2021; 53 (11): 1606‒15.
  14. Fink-Baldauf IM, et al. CRISPRi links COVID-19 GWAS loci to LZTFL1 and RAVER1. EBioMedicine. 2022; 75: 103806.
  15. Marion V, et al., Exome sequencing identifies mutations in LZTFL1, a BBSome and smoothened trafficking regulator, in a family with Bardet--Biedl syndrome with situs inversus and insertional polydactyly. J Med Genet. 2012; 49 (5): 317‒21.
  16. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, et al. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol. 2021; 16 (11): 1821‒39.
  17. Redin C, CW. Thorball, and J. Fellay, Host genomics of SARS-CoV-2 infection. Eur J Hum Genet. 2022; 30 (8): 908‒14.
  18. Wei Q, Chen ZH, Wang L, Zhang T, Duan L, Behrens C, et al. LZTFL1 suppresses lung tumorigenesis by maintaining differentiation of lung epithelial cells. Oncogene. 2016; 35 (20): 2655‒63.
  19. Angulo-Aguado M, et al., Association Between the LZTFL1 rs11385942 Polymorphism and COVID-19 Severity in Colombian Population. Front Med (Lausanne). 2022; 9: 910098.
  20. Rescenko R, et al. Replication of LZTFL1 Gene Region as a Susceptibility Locus for COVID-19 in Latvian Population. Virol Sin. 2021; 36 (5): 1241‒4.
  21. Zecevic M, et al. Genome-Wide Association Study of COVID-19 Outcomes Reveals Novel Host Genetic Risk Loci in the Serbian Population. Front Genet. 2022; 13: 911010.
  22. Niemi MEK, Daly MJ, Ganna A. The human genetic epidemiology of COVID-19. Nat Rev Genet. 2022; 23 (9): 533‒46.
  23. Fishchuk L, et al. Modifying effects of TNF-alpha, IL-6 and VDR genes on the development risk and the course of COVID-19. Pilot study. Drug Metab Pers Ther. 2021; 37 (2): 133‒9.
  24. Kudryavtsev YS, Beregov MM, Berdalin AB, Lelyuk VG. Comparison of the Main Staging Systems for Assessing the Severity of Lung Injury in Patients with COVID-19 and Evaluation of Their Predictive Value. Journal of radiology and nuclear medicine. 2021; 102 (5): 296‒303. Russian.